These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 29032012)

  • 1. Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study.
    Borgemeester RWK; van Laar T
    Parkinsonism Relat Disord; 2017 Dec; 45():33-38. PubMed ID: 29032012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients.
    Borgemeester RW; Drent M; van Laar T
    Parkinsonism Relat Disord; 2016 Feb; 23():17-22. PubMed ID: 26709292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
    Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Candidate patient for treatment with continuous apomorphine infusion].
    Martí MJ; Kulisevsky J
    Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous infusion of apomorphine in patients with advanced Parkinson's disease and different degrees of functional disability.
    Salazar G; Martín J; Fragoso M; Font MA
    Neurologia; 2017; 32(6):407-410. PubMed ID: 26699210
    [No Abstract]   [Full Text] [Related]  

  • 6. Continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: 10-year experience with 230 patients.
    Sesar Á; Fernández-Pajarín G; Ares B; Rivas MT; Castro A
    J Neurol; 2017 May; 264(5):946-954. PubMed ID: 28364292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies.
    Olivola E; Fasano A; Varanese S; Lena F; Santilli M; Femiano C; Centonze D; Modugno N
    Neurol Sci; 2019 Sep; 40(9):1917-1923. PubMed ID: 31111272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
    Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
    Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Nocturnal continuous subcutaneous infusion of apomorphine in advanced Parkinson's disease: a series of 37 cases].
    García-Fernández C; Vargas-Mendoza AK; López-López B; Blázquez-Estrada M; Suárez-San Martín ME
    Rev Neurol; 2024 Oct; 79(8):217-221. PubMed ID: 39404035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A; Turner K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early factors for predicting discontinuation to subcutaneous Apomorphine infusion in Parkinson's disease: A prospective analysis of the Thai Apomorphine Registry.
    Phokaewvarangkul O; Anan C; Phimpha A; Chaudhuri KR; van Laar T; Bhidayasiri R
    Parkinsonism Relat Disord; 2021 Oct; 91():146-151. PubMed ID: 34624769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study.
    Drapier S; Eusebio A; Degos B; Vérin M; Durif F; Azulay JP; Viallet F; Rouaud T; Moreau C; Defebvre L; Fraix V; Tranchant C; Andre K; Courbon CB; Roze E; Devos D
    J Neurol; 2016 Jun; 263(6):1111-9. PubMed ID: 27060084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Candidate patient for subcutaneous apomorphine injection].
    Chacón JR; Mata M
    Rev Neurol; 2012; 55 Suppl 1():S7-9. PubMed ID: 23169232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
    Grandas FJ; Sesar-Ignacio Á
    Rev Neurol; 2012; 55 Suppl 1():S21-4. PubMed ID: 23169229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study.
    García Ruiz PJ; Sesar Ignacio A; Ares Pensado B; Castro García A; Alonso Frech F; Alvarez López M; Arbelo González J; Baiges Octavio J; Burguera Hernández JA; Calopa Garriga M; Campos Blanco D; Castaño García B; Carballo Cordero M; Chacón Peña J; Espino Ibáñez A; Gorospe Onisalde A; Giménez-Roldán S; Granés Ibáñez P; Hernández Vara J; Ibáñez Alonso R; Jiménez Jiménez FJ; Krupinski J; Kulisevsky Bojarsky J; Legarda Ramírez I; Lezcano García E; Martínez-Castrillo JC; Mateo González D; Miquel Rodríguez F; Mir P; Muñoz Fargas E; Obeso Inchausti J; Olivares Romero J; Olivé Plana J; Otermin Vallejo P; Pascual Sedano B; Pérez de Colosía Rama V; Pérez López-Fraile I; Planas Comes A; Puente Periz V; Rodríguez Oroz MC; Sevillano García D; Solís Pérez P; Suárez Muñoz J; Vaamonde Gamo J; Valero Merino C; Valldeoriola Serra F; Velázquez Pérez JM; Yáñez Baña R; Zamarbide Capdepon I
    Mov Disord; 2008 Jun; 23(8):1130-6. PubMed ID: 18442107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years.
    Morgante L; Basile G; Epifanio A; Spina E; Antonini A; Stocchi F; Di Rosa E; Martino G; Marconi R; La Spina P; Nicita-Mauro V; Di Rosa AE
    Arch Gerontol Geriatr Suppl; 2004; (9):291-6. PubMed ID: 15207426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous subcutaneous apomorphine monotherapy in Parkinson's disease.
    Papuć E; Trzciniecka O; Rejdak K
    Ann Agric Environ Med; 2019 Mar; 26(1):133-137. PubMed ID: 30922043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.